TScan raises $100M to advance TCR-T cell therapies

Published: 29 January 2021

Proceeds from new series C financing will be used to advance TScan’s T-cell receptor (TCR) T-cell therapy pipeline for solid and liquid tumors.

New TScan investors including BlackRock, RA Capital Management, and two undisclosed healthcare funds. TScan hopes to complete IND-enabling studies for two liquid tumor programs, TSC-100 and TSC-101, and submit INDs in the second half of 2021. For the solid tumor pipeline, the company hopes to nominate a set of three target candidates in 2021, with IND submissions planned to follow in 2022. TScan also has plans to leverage its target discovery technology in infectious and autoimmune disease.

"This funding will enable TScan to progress its first two TCR-T cell assets into the clinic in 2021, with three additional programs to enter the clinic in 2022," said David Southwell, Chief Executive Officer at TScan in a press release. "I’m excited to welcome this new syndicate of distinguished healthcare investors to TScan. Recently, we have identified over 40 novel cancer targets from clinically active TCRs for development of multiplexed TCR-T cell therapies as part of our solid tumor program. Our goal is to continue to build a bank of clinically-active TCRs throughout 2021 to help patients win their fight against cancer."